Literature DB >> 27327540

Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulation.

Magali Haas1, Diane Stephenson2, Klaus Romero2, Mark Forrest Gordon3, Neta Zach4, Hugo Geerts5.   

Abstract

Many disease-modifying clinical development programs in Alzheimer's disease (AD) have failed to date, and development of new and advanced preclinical models that generate actionable knowledge is desperately needed. This review reports on computer-based modeling and simulation approach as a powerful tool in AD research. Statistical data-analysis techniques can identify associations between certain data and phenotypes, such as diagnosis or disease progression. Other approaches integrate domain expertise in a formalized mathematical way to understand how specific components of pathology integrate into complex brain networks. Private-public partnerships focused on data sharing, causal inference and pathway-based analysis, crowdsourcing, and mechanism-based quantitative systems modeling represent successful real-world modeling examples with substantial impact on CNS diseases. Similar to other disease indications, successful real-world examples of advanced simulation can generate actionable support of drug discovery and development in AD, illustrating the value that can be generated for different stakeholders.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's dementia; Brain disorders; Crowdsourcing; Private-public partnership; Quantitative systems pharmacology; Regulatory

Mesh:

Year:  2016        PMID: 27327540     DOI: 10.1016/j.jalz.2016.05.005

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  10 in total

1.  Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.

Authors:  Daniela J Conrado; Jane Larkindale; Alexander Berg; Micki Hill; Jackson Burton; Keith R Abrams; Richard T Abresch; Abby Bronson; Douglass Chapman; Michael Crowther; Tina Duong; Heather Gordish-Dressman; Lutz Harnisch; Erik Henricson; Sarah Kim; Craig M McDonald; Stephan Schmidt; Camille Vong; Xiaoxing Wang; Brenda L Wong; Florence Yong; Klaus Romero
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-24       Impact factor: 2.745

2.  Data Dissemination: Shortening the Long Tail of Traumatic Brain Injury Dark Data.

Authors:  Bridget E Hawkins; J Russell Huie; Carlos Almeida; Jiapei Chen; Adam R Ferguson
Journal:  J Neurotrauma       Date:  2019-03-29       Impact factor: 5.269

Review 3.  Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.

Authors:  Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  "Exceptions that prove the rule"-Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia-Alzheimer's disease syndrome?

Authors:  John C S Breitner; Hiroko H Dodge; Zaven S Khachaturian; Ara S Khachaturian
Journal:  Alzheimers Dement       Date:  2022-03-04       Impact factor: 16.655

Review 5.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

6.  Big Data and Healthcare: Building an Augmented World.

Authors:  Hyejung Chang; Mona Choi
Journal:  Healthc Inform Res       Date:  2016-07-31

7.  Towards a systems approach for chronic diseases, based on health state modeling.

Authors:  Michael Rebhan
Journal:  F1000Res       Date:  2017-03-23

Review 8.  Drug development in Alzheimer's disease: the path to 2025.

Authors:  Jeffrey Cummings; Paul S Aisen; Bruno DuBois; Lutz Frölich; Clifford R Jack; Roy W Jones; John C Morris; Joel Raskin; Sherie A Dowsett; Philip Scheltens
Journal:  Alzheimers Res Ther       Date:  2016-09-20       Impact factor: 6.982

9.  Standardized Data Structures in Rare Diseases: CDISC User Guides for Duchenne Muscular Dystrophy and Huntington's Disease.

Authors:  Ariana P Mullin; Diane Corey; Emily C Turner; Richard Liwski; Daniel Olson; Jackson Burton; Sudhir Sivakumaran; Lynn D Hudson; Klaus Romero; Diane T Stephenson; Jane Larkindale
Journal:  Clin Transl Sci       Date:  2020-08-25       Impact factor: 4.689

Review 10.  Biomarkers: Our Path Towards a Cure for Alzheimer Disease.

Authors:  Rawan Tarawneh
Journal:  Biomark Insights       Date:  2020-11-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.